SEC Form PREM14A filed by Cumberland Pharmaceuticals Inc.
$CPIX
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
DEFM14A - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
PREM14A - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
10-Q - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Filer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
Positive Results from Phase 2a Clinical TrialStudy met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumorsTrial revealed promising efficacy signals with fewer deaths due to metastasis in the ifetroban arm, than in the placebo arm (p=0.037)Results support development of ifetroban as a candidate for metastasis preventionNASHVILLE, Tenn., June 2, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, and Vanderbilt Health today announce data from a Phase 2a clinical trial of ifetroban to prevent metastasis in high-risk solid tumors. Th
Amid the rapidly evolving Ebola virus disease (EVD) outbreak involving the rare Bundibugyo ebolavirus sub-type, for which there are no approved medications or vaccines, RedHill Biopharma is actively discussing potential collaborations for clinical advancement of opaganib1, including the World Health Organization's (WHO) SOLIDARITY CORE clinical trial platformOpaganib EVD rationale (analogous to EVD treatment pathway):Phase 3 clinical antiviral activity (severe COVID-19) showing2:70.2% mortality reduction with opaganib given as add-on to best available standard of care (remdesivir + corticosteroids): 6.98% (n=3/43) opaganib + SoC vs. 23.4% (n=11/47) placebo + SoC (p=0.034)) Improved median ti
Commercialization in China through partnership with SciClone PharmaceuticalsExpands access to potentially life-saving antibiotic in the world's second-largest pharmaceutical marketNASHVILLE, Tenn., May 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), an innovation focused biopharmaceutical company, today announced the launch of its Vibativ® (telavancin) injection in China, following regulatory approval and a strategic partnership with SciClone Pharmaceuticals (Holdings) Limited. The launch follows a previously announced agreement granting SciClone exclusive rights to register, promote and distribute telavancin, injection across China. The product's approval by China's
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
4 - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Issuer)
NASHVILLE, Tenn., April 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2026 financial results and provide a company update after the market closes on Tuesday, May 5, 2026. A conference call will be held on May 5 at 4:30 p.m. Eastern Time to discuss the results and update.The link to register is https://register-conf.media-server.com/register/BI31a40566a8cb4846873ec8b25642be3a.Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically c
A Safe and Effective Non-Opioid Pain Management SolutionNASHVILLE, Tenn., April 16, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, today announced it has received approval from the U.S. Food and Drug Administration (FDA) for an expanded indication for its Caldolor® (ibuprofen) Injection product. The indication now includes the management of postoperative pain, and the approval coincides with the launch of a newly designed website for healthcare professionals highlighting this advancement and the evolving role of non-opioid pain management. With this update, Caldolor is indicated for use in adult and pediatric patients ages 3 months a
Sancuso – the Difference Between Life and LivingNASHVILLE, Tenn., March 17, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company today announced the launch of its new Sancuso® (granisetron transdermal system) website. The website is designed to provide health care professionals and patients with enhanced access to educational resources, clinical information and expert insights related to the prevention of chemotherapy-induced nausea and vomiting (CINV). The website also features the brand's key message: "Sancuso – the Difference between Life and Living."
Sitryx appoints Adam Mostafa as Chief Financial Officer Adam joins Sitryx with deep expertise in biotechnology capital markets, M&A and business development and strategic leadership Oxford, UK and Boston, MA – 8 September 2025 – Sitryx Therapeutics ("the Company"), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and inflammatory disease, today announces the appointment of Adam Mostafa as Chief Financial Officer (CFO), effective today. With over 25 years of experience, Adam is a seasoned biotech executive and financial leader. He joins Sitryx with a distinguished background spanning across biotech and healthcare financial
NASHVILLE, Tenn., July 19, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company, announced today that Martin Brown Jr. has joined the company's Board of Directors. Brown previously served for 10 years on the Board of directors of Brown-Forman Corporation, a large American wine and spirits company listed on the New York Stock Exchange. The brands in Brown-Forman's portfolio include Jack Daniel's and Woodford Reserve whiskeys, Benriach scotch, Herradura tequila and Finlandia vodka. Brown is an attorney at Adams and Reese LLP, a
SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)
SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)
SC 13G - CUMBERLAND PHARMACEUTICALS INC (0001087294) (Subject)